171 related articles for article (PubMed ID: 38538885)
1. Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib.
Zong Y; Tao Z; Jiang S; Wang M; Yu W
Discov Oncol; 2024 Mar; 15(1):89. PubMed ID: 38538885
[TBL] [Abstract][Full Text] [Related]
2. Exosomal microRNA profiling revealed enhanced autophagy suppression and anti-tumor effects of a combination of compound Phyllanthus urinaria and lenvatinib in hepatocellular carcinoma.
Liao M; Qin M; Liu L; Huang H; Chen N; Du H; Huang D; Wang P; Zhou H; Tong G
Phytomedicine; 2024 Jan; 122():155091. PubMed ID: 37844378
[TBL] [Abstract][Full Text] [Related]
3. shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells
Pan HM; Lang WY; Yao LJ; Wang Y; Li XL
World J Gastrointest Oncol; 2019 Aug; 11(8):622-633. PubMed ID: 31435463
[TBL] [Abstract][Full Text] [Related]
4. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.
Miyazaki K; Morine Y; Xu C; Nakasu C; Wada Y; Teraoku H; Yamada S; Saito Y; Ikemoto T; Shimada M; Goel A
Cells; 2023 Feb; 12(4):. PubMed ID: 36831279
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
Yang CJ; Wu MH; Tsai JJ; Hsu FT; Hsia TC; Liu KC; Kuo YC
Anticancer Res; 2022 May; 42(5):2495-2505. PubMed ID: 35489726
[TBL] [Abstract][Full Text] [Related]
6. KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP; Chen Y; Alejo S; He Y; Palacios BE; Loeffel I; Liu J; Pratap UP; Gray G; Achuthan Pillai SM; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Palakurthi S; Tekmal RR; Vadlamudi RK; Kost E; Sareddy GR
Cancer Lett; 2022 Jan; 524():219-231. PubMed ID: 34673129
[TBL] [Abstract][Full Text] [Related]
7. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
Cheng Y; Zhan P; Lu J; Lu Y; Luo C; Cen X; Wang F; Xie C; Yin Z
Liver Int; 2023 Jul; 43(7):1577-1592. PubMed ID: 37208925
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.
Sun D; Liu J; Wang Y; Dong J
Front Oncol; 2022; 12():944537. PubMed ID: 36158676
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib Suppresses Protein Kinase B Signaling and Induces Apoptosis in Osteosarcoma Cells.
Li CY; Chen HC; Liao CY; Hsu FT; Hung KC; Liu KC; Chen JC; Ku MC
Anticancer Res; 2024 Jan; 44(1):85-92. PubMed ID: 38160012
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT.
Ye J; Qi L; Liang J; Zong K; Liu W; Li R; Feng R; Zhai W
J Cancer; 2021; 12(12):3548-3557. PubMed ID: 33995632
[TBL] [Abstract][Full Text] [Related]
11. LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.
Wang Z; Gao S; Han D; Han W; Li M; Cai C
Front Oncol; 2019; 9():721. PubMed ID: 31428587
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib Inhibits AKT/NF-κB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.
Liu YC; Huang BH; Chung JG; Liu WL; Hsu FT; Lin SS
Anticancer Res; 2021 Jan; 41(1):123-130. PubMed ID: 33419805
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
[TBL] [Abstract][Full Text] [Related]
15. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Chen C; Wang Y; Wang S; Liu Y; Zhang J; Xu Y; Zhang Z; Bao W; Wu S
Int J Oncol; 2017 Mar; 50(3):942-952. PubMed ID: 28098854
[TBL] [Abstract][Full Text] [Related]
16. Low Dose of 5-Aminolevulinic Acid Hydrochloride Alleviates the Damage in Cardiomyocytes Induced by Lenvatinib via PI3K/AKT Signaling Pathway.
Shi Y; Hu F; Fu H; Li S; Lu C; Hu C
Discov Med; 2023 Aug; 35(177):483-491. PubMed ID: 37553302
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.
Zhu Y; Sun P; Wang K; Xiao S; Cheng Y; Li X; Wang B; Li J; Yu W; Cheng Y
Cancer Cell Int; 2021 Sep; 21(1):503. PubMed ID: 34537075
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
20. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.
Guo DZ; Zhang SY; Dong SY; Yan JY; Wang YP; Cao Y; Rao SX; Fan J; Yang XR; Huang A; Zhou J
Front Immunol; 2023; 14():1141199. PubMed ID: 36911686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
